Audit and Research

The numbers of cataract surgeries performed, visual outcomes and posterior capsule rupture (PCR) rates are shown in Figures 1.1 to 1.3.

Benchmarks of success

Table 1.1 Outcomes of cataract surgery from international studies and at SNEC
Title of study	Country	Number of cases	BCVA 6/12 or better with ocular comorbidity
No (%) Yes (%)
The Cataract National Dataset electronic multi-centre audit of 55,567 operations: updating benchmark standards of care in the United Kingdom and internationally (laycock et al., 2009	UK	55,567	94.7	79.9
Determination of valid benchmarks for outcome indicators in cataract surgery: a multicentre, prospective cohort trial (Hanh et al., 2011)	Germany	1,685	98.5	-
Visual outcome of cataract surgery; study from the European Registry of Quality Outcomes for Cataract and Refractive Surgery (Lundstrom, Barry, Henry, Rosen, & Stenevi, 2013)	15 European countries	368,256	98.2	94.3
SNEC (main centre) 2014 audit data – phacoemulsification outcomes	Singapore	13,682	99.3	-

References

Hahn, U., Krummenauer, F., Kolbl, B., Neuhann, T., Schayan-Araghi, K., Schmickler, S., & Neuhann, I. (2011). Determination of valid benchmarks for outcome indicators in cataract surgery; a multicentre, prospective cohort trial. Ophthalmology, 118, 2105-2112.
Jaycock, P., Johnston, R. L., Taylor, H., Adams, M., Tole, D. M., Galloway, P., & Sparrow, J. M. (2009). The Cataract National Dataset electronic multi-centre audit of 55,567 operations: updating benchmark standards of care in the United Kingdom and internationally. Eye, 23, 38-49.
Lundstrom, M., Barry, P., Henry, Y., Rosen, P., & Stenevi, U. (2013). Visual outcome of cataract surgery; study from the European Registry of Quality Outcomes for Cataract and Refractive Surgery. Journal of Cataract & Refractive Surgery, 39, 673-679.

Our Care Team

Back to Clinical Interests

Our Care Team

News

Research Formosa Pharmaceuticals and SERI Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – Formosa Pharmaceuticals, Inc. (“Formosa”, 6838.TW) and the Singapore Eye Research Institute (“SERI”) are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI’s world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD. The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice. Synergy of Innovation and Clinical Excellence A/Prof Yu-Chi Liu, clinician scientist at Singapore National Eye Center and Principal Investigator at SERI, brings extensive experience in corneal neuropathy and translational medicine to the collaboration. Her recent work in diabetic keratopathy and ocular surface inflammation will be pivotal in guiding the development of formulations targeting complex anterior segment conditions. "Collaborating with Formosa Pharmaceuticals allows us to bridge the gap between benchside innovation and bedside application," said A/Prof. Yu-Chi Liu. "Our goal is to utilize advanced formulation technologies like APNT to create treatments that are not only more effective but also less burdensome for patients suffering from ocular conditions." Leveraging APNT® Technology Formosa Pharmaceuticals’ APNT® platform specializes in reducing the particle size of active pharmaceutical ingredients (APIs) to stable, uniform nanoparticles. This technology is a hallmark of Formosa's development pipeline, offering a powerful solution for improving the delivery of poorly soluble drugs to the target tissues and organs. "We are honored to work alongside Professor Liu and her distinguished team at SERI," said Erick Co, President & CEO of Formosa Pharmaceuticals. "Initial efforts have confirmed compatibility of APNT and SERI’s research models and prompt us to extend our partnership. SERI’s reputation for excellence in vision research, backed by their comprehensive capabilities and facilities, are unparalleled. Together, we are excited to translate the research findings into better clinical outcomes."

30 Apr 2026 Read Story

Education Singapore National Eye Centre and Singapore Polytechnic collaborate to strengthen optometrists’ role in community eye care The partnership will see both parties co-develop the Clinical Decision-Making in Community Optometry training programme for practicing community optometrists to build on their competencies to deliver quality eye care in the community.

05 Mar 2026 Read Story

View All

Cataract & Comprehensive Ophthalmology